Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Support

This activity is supported by an educational grant from Sanofi Genzyme.

Advances in™ Pompe Disease: Opportunities to Improve Prognosis Through Early Detection and New Treatments

Release Date: July 31, 2020
Expiration Date: July 31, 2021

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of Pompe disease, with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of diagnosis, current and emerging treatment strategies, and improvements in multispecialty management for Pompe disease will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward pediatricians and medical specialists who have the opportunity to recognize Pompe disease such as hematologists, oncologists, cardiologists, neurologists, growth specialists, pulmonologists, gastroenterologists, hepatologists, geneticists, and ear, nose, and throat specialists. Additionally, nurse practitioners (NPs), physician assistants (PAs), nurses and other health care professionals who are involved in the diagnosis and management of Pompe disease will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Recognize the genetic etiology and known pathophysiological mechanisms involved in Pompe disease and differentiate between phenotypic disease classifications
  • Identify the clinical presentation of Pompe disease, including the variability and unpredictability of symptoms in some patients, and the importance of early diagnosis
  • Evaluate the efficacy and safety of investigational enzyme replacement therapy (ERT) for patients with Pompe disease

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Kenneth I. Berger, MD
Kenneth I. Berger, MD
Professor of Medicine, Neuroscience and Physiology
Division of Pulmonary, Critical Care and Sleep Medicine
New York University School of Medicine
Director, André Cournand Pulmonary Physiology Research Laboratory,
Bellevue Hospital
New York, NY

Disclosures: Consultant: Sanofi / Genzyme, Amicus Therapeutics, Spark Therapeutics

Priya Kishnani, MD
Priya Kishnani, MD
C.L. and Sue Chen Professor of Pediatrics
Department of Pediatrics
Division Chief, Medical Genetics
Division of Medical Genetics
Duke University Medical Center
Durham, NC

Disclosures: Grant Research Support: Sanofi Genzyme, Valerion Therapeutics LLC, Amicus Therapeutics Inc; Consultant: Sanofi Genzyme, Amicus Therapeutics Inc, Vertex Pharmaceuticals Inc, Asklepios BioPharmaceutical Inc; Stock/Shareholders: Asklepios BioPharmaceutical Inc

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By